Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors

NCT07204340 is registered in ClinicalTrials.gov with Treeline Biosciences, Inc. as lead sponsor.

NCT NCT07204340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors
Lead sponsor
Treeline Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 29, 2025
Completion date
April 1, 2032
Enrollment
270 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

kras mutant solid tumors